Between the Bells

From the helm: Amplia Therapeutics (ASX:ATX), CEO & MD, Christopher Burns & Bell Potter Analyst, Thomas Wakim.

·14 min·1 clip
A pancreatic cancer patient on Amplia's trial had their tumor shrink to just dead tissue, a rare complete response.
Listen to the show on